248 related articles for article (PubMed ID: 35343031)
1. Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2022 Jun; 27(3):e12886. PubMed ID: 35343031
[TBL] [Abstract][Full Text] [Related]
2. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
3. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2021 Oct; 26(5):e12837. PubMed ID: 34278663
[TBL] [Abstract][Full Text] [Related]
4. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects.
Fendrick AM; McCort JT; Chernew ME; Hirth RA; Patel C; Bloom BS
Am J Gastroenterol; 1997 Nov; 92(11):2017-24. PubMed ID: 9362183
[TBL] [Abstract][Full Text] [Related]
5. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis.
Ladabaum U; Chey WD; Scheiman JM; Fendrick AM
Aliment Pharmacol Ther; 2002 Aug; 16(8):1491-501. PubMed ID: 12182749
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
[TBL] [Abstract][Full Text] [Related]
7. Critical issues in the pathophysiology and management of peptic ulcer disease.
Hunt RH; Malfertheiner P; Yeomans ND; Hawkey CJ; Howden CW
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):685-99. PubMed ID: 8590166
[TBL] [Abstract][Full Text] [Related]
8. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.
Ford AC; Delaney BC; Forman D; Moayyedi P
Am J Gastroenterol; 2004 Sep; 99(9):1833-55. PubMed ID: 15330927
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Helicobacter pylori eradication therapy in cirrhotic patients with peptic ulcer disease.
Mitrică D; Pleşa A; Constantinescu R; Drug V; Stanciu C
Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):367-74. PubMed ID: 21870725
[TBL] [Abstract][Full Text] [Related]
10. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease.
Tomita T; Fukuda Y; Tamura K; Tanaka J; Hida N; Kosaka T; Hori K; Sakagami T; Satomi M; Shimoyama T
Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():204-9. PubMed ID: 11966543
[TBL] [Abstract][Full Text] [Related]
11. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
Bianchi Porro G; Parente F; Imbesi V; Montrone F; Caruso I
Gut; 1996 Jul; 39(1):22-6. PubMed ID: 8881802
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
[TBL] [Abstract][Full Text] [Related]
13. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.
Gisbert JP; Khorrami S; Carballo F; Calvet X; Gené E; Dominguez-Muñoz JE
Cochrane Database Syst Rev; 2004; (2):CD004062. PubMed ID: 15106235
[TBL] [Abstract][Full Text] [Related]
14. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.
Gisbert JP; Khorrami S; Carballo F; Calvet X; Gené E; Dominguez-Muñoz JE
Cochrane Database Syst Rev; 2003; (4):CD004062. PubMed ID: 14584003
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based clinical practice guidelines for peptic ulcer disease 2015.
Satoh K; Yoshino J; Akamatsu T; Itoh T; Kato M; Kamada T; Takagi A; Chiba T; Nomura S; Mizokami Y; Murakami K; Sakamoto C; Hiraishi H; Ichinose M; Uemura N; Goto H; Joh T; Miwa H; Sugano K; Shimosegawa T
J Gastroenterol; 2016 Mar; 51(3):177-94. PubMed ID: 26879862
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness in Canada of a multidrug prepackaged regimen (Hp-PAC)+ for Helicobacter pylori eradication.
Agro K; Blackhouse G; Goeree R; Willan AR; Huang JQ; Hunt RH; O'Brien BJ
Pharmacoeconomics; 2001; 19(8):831-43. PubMed ID: 11596835
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.
Roderick P; Davies R; Raftery J; Crabbe D; Pearce R; Patel P; Bhandari P
J Med Screen; 2003; 10(3):148-56. PubMed ID: 14561268
[TBL] [Abstract][Full Text] [Related]
18. H. pylori eradication lower ulcers in cirrhosis. [Corrected].
Chang SS; Hu HY
J Dig Dis; 2014 Aug; 15(8):451-8. PubMed ID: 24825443
[TBL] [Abstract][Full Text] [Related]
19. Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease.
Penston JG
Aliment Pharmacol Ther; 1996 Aug; 10(4):469-86. PubMed ID: 8853751
[TBL] [Abstract][Full Text] [Related]
20. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Kowada A
Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
